MCID: GST037
MIFTS: 56

Gastroparesis

Categories: Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 53 29 55 44 15 73
Delayed Gastric Emptying 53
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD10 33 K31.84
ICD9CM 35 536.3
MeSH 44 D018589
NCIt 50 C80512
UMLS 73 C0152020

Summaries for Gastroparesis

NIH Rare Diseases : 53 Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis,  the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease.  In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery.  Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride.  With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to stomach disease and dyspepsia, and has symptoms including hemiplegia, ophthalmoplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Domperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, testes and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Gastroparesis (GP also called delayed gastric emptying) is a medical condition consisting of a paresis... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 stomach disease 30.2 CCK GAST GHRL MLN MLNR
2 dyspepsia 29.6 CCK GHRL HTR3A
3 duodenogastric reflux 29.5 CCK GAST MLN
4 gastroesophageal reflux 28.9 CCK GAST GHRL MLN
5 anxiety 28.8 CCK CYP2D6 HTR3A
6 constipation 28.3 CCK GAST HTR3A MLN MLNR
7 brittle diabetes 10.9
8 galactorrhea 10.6 CYP2D6 DRD2
9 codeine toxicity 10.6 ABCB1 CYP2D6
10 tardive dyskinesia 10.6 CYP2D6 DRD2
11 functional colonic disease 10.5 MLN MLNR
12 colonic pseudo-obstruction 10.4 MLN MLNR
13 neuroleptic malignant syndrome 10.4 CYP2D6 DRD2
14 opioid abuse 10.3 CCK DRD2
15 paralytic ileus 10.3 ABCB1 CCK
16 non-functioning pancreatic endocrine tumor 10.3 GAST GHRL
17 nasal cavity adenocarcinoma 10.2 CCK GAST
18 pancreatic cholera 10.2 CCK GAST
19 duodenal gastrinoma 10.2 CCK GAST
20 pylorospasm 10.1 GAST GHRL MLN
21 diabetes mellitus 10.1
22 postcholecystectomy syndrome 10.1 CCK GAST MLN
23 opioid addiction 10.1 ABCB1 CCK DRD2
24 pancreatic steatorrhea 10.0 CCK GHRL
25 disease of mental health 10.0 CCK CYP2D6 DRD2
26 pancreatitis 10.0
27 neuronitis 10.0
28 neuropathy 10.0
29 early-onset schizophrenia 9.9 DRD2 HTR3A
30 small cell cancer of the lung 9.9
31 psychotic disorder 9.9 CYP2D6 DRD2 HTR3A
32 obsessive-compulsive disorder 9.9 CYP2D6 DRD2 HTR3A
33 cataract 14, multiple types 9.9 CCK GAST
34 eating disorder 9.9 CCK DRD2 GHRL
35 migraine with or without aura 1 9.9 CYP2D6 DRD2 HTR3A
36 serotonin syndrome 9.8 CYP2D6 GAST HTR3A
37 lung cancer 9.8
38 esophagitis 9.8
39 autonomic dysfunction 9.8
40 dysphagia 9.8
41 functional diarrhea 9.8 GHRL HTR3A
42 multiple sclerosis 9.8
43 cystic fibrosis 9.8
44 pancreatic cancer 9.8
45 gastric cancer 9.8
46 cholangiocarcinoma 9.8
47 morbid obesity 9.8
48 atrial fibrillation 9.8
49 autonomic neuropathy 9.8
50 demyelinating disease 9.8

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


hemiplegia, ophthalmoplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.32 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.32 GHSR
3 Decreased viability GR00381-A-3 9.32 GHSR HTR3A MLN
4 Decreased viability GR00402-S-2 9.32 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.5 ABCB1 CCK DRD2 GAST GHRL HMOX1
2 homeostasis/metabolism MP:0005376 9.28 ABCB1 CCK DRD2 GAST GHRL GHSR

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57808-66-9 3151
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Esomeprazole Approved, Investigational Phase 4,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
4
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53608-75-6
5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
7
Carbidopa Approved Phase 4 28860-95-9 34359 38101
8
Levodopa Approved Phase 4,Phase 2,Not Applicable 59-92-7 6047
9
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
11
Tadalafil Approved, Investigational Phase 4,Phase 2 171596-29-5 110635
12
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
13
Ticagrelor Approved Phase 4 274693-27-5 9871419
14
Thrombin Approved, Investigational Phase 4
15
Haloperidol Approved Phase 4 52-86-8 3559
16
Exenatide Approved, Investigational Phase 4,Phase 1,Phase 2 141758-74-9 15991534
17
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
18 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
19
Butyric Acid Experimental, Investigational Phase 4,Phase 2 107-92-6 264
20 Anticoagulants Phase 4,Not Applicable
21 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Calcium, Dietary Phase 4,Not Applicable
24 Chelating Agents Phase 4,Not Applicable
25 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 glucagon Phase 4
32 Glucagon-Like Peptide 1 Phase 4
33 Antacids Phase 4,Phase 1,Not Applicable
34 Anti-Ulcer Agents Phase 4,Phase 1,Not Applicable
35 Proton Pump Inhibitors Phase 4,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Hormones Phase 4,Phase 1,Phase 2
38 Coagulants Phase 4,Not Applicable
39 Fibrin Tissue Adhesive Phase 4,Phase 3,Not Applicable
40 Hemostatics Phase 4,Not Applicable
41 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Incretins Phase 4,Phase 1,Phase 2,Not Applicable
44 Antiparkinson Agents Phase 4,Not Applicable
45 Carbidopa, levodopa drug combination Phase 4
46 Dihydroxyphenylalanine Phase 4,Phase 2
47 Dopamine agonists Phase 4
48 Emetics Phase 4
49 Cortisol succinate Phase 4,Phase 2
50 Hormone Antagonists Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 274)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
4 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
5 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
6 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
7 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
8 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Recruiting NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
9 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
10 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
11 An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
12 An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
13 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
14 Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis Terminated NCT00390975 Phase 4 Tegaserod
15 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
16 An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects Terminated NCT02793154 Phase 4 Exenatide;Albiglutide
17 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
18 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
19 Sancuso® for Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
20 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
21 A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Unknown status NCT01460550 Phase 3
22 Nortriptyline for Idiopathic Gastroparesis Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
23 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
24 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
25 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
26 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed NCT01149369 Phase 3 Aprepitant;Placebo
27 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
28 Standardization of Surgery on the Pancreatic Cancer Completed NCT00679913 Phase 3
29 Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy Completed NCT01544790 Phase 3
30 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Recruiting NCT03383146 Phase 3 Relamorelin;Placebo
31 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02 Recruiting NCT03426345 Phase 3 Relamorelin;Placebo
32 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Recruiting NCT03285308 Phase 3 Relamorelin;Placebo
33 Prucalopride Versus Placebo in Gastroparesis Recruiting NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
34 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
35 Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve Recruiting NCT02524626 Phase 3
36 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Active, not recruiting NCT02457156 Phase 3 Octreotide
37 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
38 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
39 REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY) Not yet recruiting NCT03030170 Phase 3
40 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
41 Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy Not yet recruiting NCT03398291 Phase 3 Standard chemotherapy
42 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy Not yet recruiting NCT03419676 Phase 3
43 PoLyethylene Glycolic Acid Mesh reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial) Not yet recruiting NCT03331718 Phase 3 PGA mesh reinforcement
44 Acupuncture for Diabetic Gastroparesis Suspended NCT00470795 Phase 3
45 Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus Terminated NCT00228891 Phase 2, Phase 3
46 The Use of Domperidone for Gastroparesis Withdrawn NCT01378884 Phase 3 Domperidone
47 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
48 Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Withdrawn NCT00228904 Phase 2, Phase 3
49 Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo
50 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Genetic tests related to Gastroparesis:

# Genetic test Affiliating Genes
1 Gastroparesis 29

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

41
Small Intestine, Testes, Bone, Pancreas, Colon, Lung, Liver

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 739)
# Title Authors Year
1
Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. ( 29111279 )
2018
2
G-POEM for Gastroparesis: Is There Pressure to Go with the Flow? ( 29855769 )
2018
3
Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. ( 29808246 )
2018
4
The effect of extracorporeal low-energy shockwave on diabetic gastroparesis in a rat model. ( 29966170 )
2018
5
Pyloric sphincter characteristics using EndoFLIP<sup>Ar</sup> in gastroparesis. ( 29709494 )
2018
6
Delivery of Mesenchymal Stem Cells from Gelatin-Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis. ( 29414870 )
2018
7
A Critical Review of the Current Clinical Landscape of Gastroparesis. ( 29928159 )
2018
8
LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells. ( 29317209 )
2018
9
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. ( 29111115 )
2018
10
Therapeutic response to domperidone in gastroparesis: AA prospective study using the GCSI-daily diary. ( 29110425 )
2018
11
The Challenges of Gastroparesis: Changing Study Design to Improve Clinical Care. ( 29875453 )
2018
12
Gastric per-oral endoscopic myotomy for refractory gastroparesis: a detailed description of the procedure, our experience, and review of the literature. ( 29435752 )
2018
13
Gastroparesis following resection of a fourth ventricle ependymoma in a child. ( 29933085 )
2018
14
Diabetic Gastroparesis: Principles and Current Trends in Management. ( 29934758 )
2018
15
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. ( 29795419 )
2018
16
Post-pancreatitis diabetes mellitus and gastroparesis: driven together? ( 29914234 )
2018
17
Characterizing Abdominal Pain in Patients With Gastroparesis Into Neuropathic and Nociceptive Components. ( 29782470 )
2018
18
Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study. ( 29205691 )
2018
19
Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. ( 29895073 )
2018
20
Endoscopic Therapies for Gastroparesis. ( 29687294 )
2018
21
Gastric Peroral Endoscopic Pyloromyotomy Reduces Symptoms, Increases Quality of Life, and Reduces Health Care Use For Patients With Gastroparesis. ( 29660525 )
2018
22
Challenges in defining, diagnosing, and treating diabetic gastroparesis. ( 29198995 )
2018
23
The Investigation and Treatment of Diabetic Gastroparesis. ( 29748143 )
2018
24
State of the art review with literature summary on gastric peroral endoscopic pyloromyotomy for gastroparesis. ( 29806114 )
2018
25
Glass half empty? Lessons learned about gastroparesis. ( 29862014 )
2018
26
Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. ( 29745434 )
2018
27
A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. ( 29153755 )
2018
28
Cajal Cell Counts are Important Predictors of Outcomes in Drug Refractory Gastroparesis Patients With Neurostimulation. ( 29672439 )
2018
29
Endoscopic aspects of temporary gastric electrical stimulatorA leadA placement in patients with gastroparesis andA gastroparesis-like syndromes. ( 29916475 )
2018
30
Gastroparesis: Medical and Therapeutic Advances. ( 28721575 )
2017
31
POEMs for gastroparesis. ( 27986106 )
2017
32
Reactive oxygen species overproduction and MAP kinase phosphatase-1 degradation are associated with gastroparesis in a streptozotocin-induced male diabetic rat model. ( 29094779 )
2017
33
Impaired insulin/IGF-1 is responsible for diabetic gastroparesis by damaging myenteric cholinergic neurons and interstitial cells of Cajal. ( 28931726 )
2017
34
Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. ( 29161307 )
2017
35
Effectiveness and feasibility of robotic gastric neurostimulator placement in patients with refractory gastroparesis. ( 28730536 )
2017
36
Tailored approach to gastroparesis significantly improves symptoms. ( 28779255 )
2017
37
Is There a Role for Enterohormones in the Gastroparesis of Critically Ill Patients? ( 28737574 )
2017
38
Gastric peroral endoscopic myotomy for gastroparesis, after botulinum toxin injection. ( 28759929 )
2017
39
Analysis of the Relationship between<i>Helicobacter pylori</i>Infection and Diabetic Gastroparesis. ( 29133755 )
2017
40
&amp;quot;First Do No Harm&amp;quot;: Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. ( 28932929 )
2017
41
A quantified risk-scoring system and rating model for postsurgical gastroparesis syndrome in gastric cancer patients. ( 28743171 )
2017
42
Gastroparesis: pharmacotherapy and cardiac risk. ( 29157021 )
2017
43
Exploring the Diabetic Gastroparesis Patient Experience: Patient Exit Interviews. ( 29079987 )
2017
44
Modified Laparoscopic Pyloroplasty During Laparoscopic Splenectomy and Azygoportal Disconnection for the Prevention of Postoperative Gastroparesis. ( 28689488 )
2017
45
Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( 28646590 )
2017
46
Patients with symptoms of delayed gastric emptying have a high prevalence of oesophageal dysmotility, irrespective of scintigraphic evidence of gastroparesis. ( 29177065 )
2017
47
Hot Off the Press: SGEM#196: Gastroparesis-I Feel Like Throwing Up. ( 29245179 )
2017
48
Gastric peroral endoscopic pyloromyotomy as a salvage therapy for refractory gastroparesis: a case series of different subtypes. ( 28028897 )
2017
49
Exploration of the psychosocial issues associated with gastroparesis: A qualitative investigation. ( 28071866 )
2017
50
Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. ( 28872760 )
2017

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 8.92 CCK DRD2 GHRL HTR3A

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.91 CCK GAST GHRL MLN
2 excitatory postsynaptic potential GO:0060079 9.71 DRD2 GHRL HTR3A
3 response to nicotine GO:0035094 9.64 DRD2 HMOX1
4 hormone-mediated signaling pathway GO:0009755 9.64 GHRL GHSR
5 response to cocaine GO:0042220 9.63 DRD2 HTR3A
6 positive regulation of sprouting angiogenesis GO:1903672 9.63 GHRL GHSR
7 response to food GO:0032094 9.62 GAST GHSR
8 decidualization GO:0046697 9.62 GHRL GHSR
9 positive regulation of vascular endothelial cell proliferation GO:1905564 9.61 GHRL GHSR
10 actin polymerization or depolymerization GO:0008154 9.59 GHRL GHSR
11 positive regulation of growth GO:0045927 9.58 GHRL GHSR
12 adult feeding behavior GO:0008343 9.58 GHRL GHSR
13 negative regulation of appetite GO:0032099 9.57 CCK GHSR
14 positive regulation of growth hormone secretion GO:0060124 9.56 DRD2 GHRL
15 negative regulation of interleukin-1 beta production GO:0032691 9.55 GHRL GHSR
16 negative regulation of tumor necrosis factor secretion GO:1904468 9.52 GHRL GHSR
17 growth hormone secretion GO:0030252 9.51 GHRL GHSR
18 G-protein coupled receptor signaling pathway GO:0007186 9.5 CCK DRD2 GAST GHRL GHSR MLN
19 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.49 GHRL GHSR
20 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.48 GHRL GHSR
21 positive regulation of appetite GO:0032100 9.46 GHRL GHSR
22 positive regulation of eating behavior GO:1904000 9.43 GHRL GHSR
23 positive regulation of multicellular organism growth GO:0040018 9.43 DRD2 GHRL GHSR
24 regulation of transmission of nerve impulse GO:0051969 9.4 GHRL GHSR
25 regulation of gastric motility GO:1905333 9.37 GHRL GHSR
26 positive regulation of small intestine smooth muscle contraction GO:1904349 9.32 GHRL GHSR
27 positive regulation of small intestinal transit GO:0120058 9.16 GHRL GHSR
28 negative regulation of insulin secretion GO:0046676 8.8 DRD2 GHRL GHSR
29 signal transduction GO:0007165 10.14 CCK DRD2 GAST GHSR HTR3A MLNR

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth hormone-releasing hormone receptor activity GO:0016520 8.96 GHSR MLNR
2 hormone activity GO:0005179 8.92 CCK GAST GHRL MLN

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....